In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 300 of 375

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]	Technology appraisal guidance	18 November 2026
Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]	Technology appraisal guidance	10 February 2027
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke	Interventional procedures guidance	11 February 2027
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism	HealthTech guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Pharmalgen for the treatment of bee and wasp venom allergy	Technology appraisal guidance	TBC
PillCam COLON 2 for investigation of the colon through direct visualisation	Diagnostics guidance	TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance	TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	24 February 2027
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	17 September 2026
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	TBC
Polycystic ovary syndrome: assessment and management	NICE guideline	9 December 2026
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance	TBC
Prostate cancer: diagnosis and management (update)	NICE guideline	TBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]	Technology appraisal guidance	TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]	Technology appraisal guidance	8 July 2026
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]	Technology appraisal guidance	TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]	Technology appraisal guidance	10 June 2026
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]	Technology appraisal guidance	TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]	Technology appraisal guidance	TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]	Technology appraisal guidance	16 December 2026
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]	Technology appraisal guidance	TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]	Technology appraisal guidance	TBC
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]	Technology appraisal guidance	TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]	Technology appraisal guidance	TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]	Technology appraisal guidance	TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]	Technology appraisal guidance	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	TBC
Secukinumab for treating giant cell arteritis in people 50 years and over [ID6563]	Technology appraisal guidance	TBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance	TBC
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]	Technology appraisal guidance	14 May 2026
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance	TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]	Technology appraisal guidance	10 February 2027

Results per page

10
25
50
All